Giulia Rizzuto

695 total citations
13 papers, 169 citations indexed

About

Giulia Rizzuto is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Giulia Rizzuto has authored 13 papers receiving a total of 169 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 6 papers in Epidemiology and 4 papers in Immunology. Recurrent topics in Giulia Rizzuto's work include Inflammatory Bowel Disease (11 papers), Microscopic Colitis (5 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Giulia Rizzuto is often cited by papers focused on Inflammatory Bowel Disease (11 papers), Microscopic Colitis (5 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Giulia Rizzuto collaborates with scholars based in Italy. Giulia Rizzuto's co-authors include Sara Renna, Ambrogio Orlando, Mario Cottone, Fabio Salvatore Macaluso, Rosalba Orlando, Filippo Mocciaro, Marco Ventimiglia, Emanuele Sinagra, Sebastiano Siringo and Marcello Maida and has published in prestigious journals such as Inflammatory Bowel Diseases, Scandinavian Journal of Gastroenterology and Journal of Crohn s and Colitis.

In The Last Decade

Giulia Rizzuto

13 papers receiving 167 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Giulia Rizzuto Italy	7	159	130	37	27	23	13	169
Luisa de Castro Spain	6	160 1.0×	133 1.0×	54 1.5×	25 0.9×	17 0.7×	9	176
Keith Friedenberg United States	5	108 0.7×	76 0.6×	62 1.7×	13 0.5×	28 1.2×	7	186
Vishal Patel United States	5	109 0.7×	101 0.8×	31 0.8×	19 0.7×	34 1.5×	11	158
Robert Boulton-Jones United Kingdom	3	138 0.9×	136 1.0×	35 0.9×	12 0.4×	9 0.4×	3	157
María Josefina Etchevers Spain	6	193 1.2×	158 1.2×	92 2.5×	13 0.5×	11 0.5×	10	218
I.A. Mouzas Greece	4	250 1.6×	220 1.7×	93 2.5×	23 0.9×	19 0.8×	7	305
Marijana Protić United States	8	160 1.0×	138 1.1×	56 1.5×	36 1.3×	12 0.5×	33	222
Anders Forss Sweden	8	141 0.9×	138 1.1×	78 2.1×	21 0.8×	21 0.9×	33	196
Alejandro Hernández-Camba Spain	7	73 0.5×	57 0.4×	41 1.1×	25 0.9×	14 0.6×	34	147
P. Hindryckx Belgium	4	94 0.6×	96 0.7×	43 1.2×	33 1.2×	6 0.3×	4	152

Countries citing papers authored by Giulia Rizzuto

Since Specialization

Citations

This map shows the geographic impact of Giulia Rizzuto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giulia Rizzuto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giulia Rizzuto more than expected).

Fields of papers citing papers by Giulia Rizzuto

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giulia Rizzuto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giulia Rizzuto. The network helps show where Giulia Rizzuto may publish in the future.

Co-authorship network of co-authors of Giulia Rizzuto

This figure shows the co-authorship network connecting the top 25 collaborators of Giulia Rizzuto. A scholar is included among the top collaborators of Giulia Rizzuto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giulia Rizzuto. Giulia Rizzuto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Maida, Marcello, Alessandro Vitello, Giulia Rizzuto, et al.. (2022). P347 Sarcopenia is a poor prognostic factor for endoscopic outcomes in patients with Crohn’s disease. Journal of Crohn s and Colitis. 16(Supplement_1). i360–i361. 2 indexed citations

Macaluso, Fabio Salvatore, Walter Fries, Sara Renna, et al.. (2021). P305 Effectiveness and Safety of Vedolizumab in Biologic-Naïve Patients: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD). Journal of Crohn s and Colitis. 15(Supplement_1). S333–S333. 1 indexed citations

Maida, Marcello, Sara Renna, Filippo Mocciaro, et al.. (2021). Blood-based prognostic biomarkers in Crohn’s Disease patients on biologics: a promising tool to predict endoscopic outcomes. Expert Opinion on Biological Therapy. 21(8). 1133–1141. 6 indexed citations

Macaluso, Fabio Salvatore, Walter Fries, Sara Renna, et al.. (2020). Effectiveness and safety of vedolizumab in biologically naïve patients: A real‐world multi‐centre study. United European Gastroenterology Journal. 8(9). 1045–1055. 22 indexed citations

Macaluso, Fabio Salvatore, Rosalba Orlando, Walter Fries, et al.. (2018). The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. Digestive and Liver Disease. 50(7). 675–681. 26 indexed citations

Macaluso, Fabio Salvatore, Marco Ventimiglia, Sara Renna, et al.. (2018). The Addition of an Immunosuppressant After Loss of Response to Anti-TNFα Monotherapy in Inflammatory Bowel Disease: A 2-Year Study. Inflammatory Bowel Diseases. 24(2). 394–401. 17 indexed citations

Macaluso, Fabio Salvatore, Marco Ventimiglia, Sara Renna, et al.. (2017). P387 The addition of an immunosuppressant is an effective optimization strategy after loss of response to anti-TNF-alpha monotherapy in patients with inflammatory bowel disease: a two-year experience. Journal of Crohn s and Colitis. 11(suppl_1). S274–S274. 13 indexed citations

Macaluso, Fabio Salvatore, Sara Renna, Marcello Maida, et al.. (2017). Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience. Scandinavian Journal of Gastroenterology. 52(9). 1–7. 21 indexed citations

Macaluso, Fabio Salvatore, Marcello Maida, Sara Renna, et al.. (2016). Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants. Digestive and Liver Disease. 49(2). 157–162. 5 indexed citations

10.

Orlando, Ambrogio, Sara Renna, Filippo Mocciaro, et al.. (2016). Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study. Digestive and Liver Disease. 48(11). 1314–1317. 4 indexed citations

11.

Mocciaro, Filippo, Sara Renna, Ambrogio Orlando, et al.. (2012). Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: Early and long-term data from a retrospective observational study. Journal of Crohn s and Colitis. 6(6). 681–686. 49 indexed citations

12.

Orlando, A., et al.. (2011). P.1.203: TREATMENT OF PERIANAL CROHN'S DISEASE: EFFICACY AND SAFETY OF A MULTIDISCIPLINARY APPROACH IN A TERTIARY REFERRAL CENTRE. Digestive and Liver Disease. 43. S215–S215. 2 indexed citations

13.

Cappello, Michael, et al.. (2009). HEPATOBILIARY COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE. Digestive and Liver Disease. 41. S126–S126. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact